

Background

ImmuKnow, an immune cell function assay, provides information about the immune suppression status of a transplant patient. This assay measures the ATP response of stimulated CD4+ peripheral blood lymphocytes.

- Patients may have an increased risk of infection due to over-immunosuppression.¹
- Under-immunosuppression carries a risk of rejection.¹
- Used over time, the assay provides important qualitative information about global changes in immune function.²
- Early indicator of immune function.²
- Immune cell monitoring provides information after adjustments in drug therapy.³


The LabCorp Advantage

- More than 1700 Patient Service Centers available nationwide.
- Staff available for support and consultation.
- Flexible connectivity options for test ordering and results
- Broad network of managed care health plans.

For additional information about

LabCorp's testing services, call 800-533-1037 or email at HLACS@LabCorp.com

Longitudinal Assessment of Post-transplant Immune Status



Clinical Indication

Monitoring of individuals undergoing immunosuppressive therapy

Test Name	Test Number
ImmuKnow	176120

For additional information, including specimen requirements, CPT coding, and RUO/IUO status, consult the online Test Menu at www.labcorp.com.

References

1. Kobashigawa JA, Kiyosaki KK, Patel JK, et al. Benefit of immune monitoring in heart transplant patients using ATP production in activeated lymphocytes. J Heart Lung Transplant. 2010;29:504-508. 2. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an Immune Function Assay. Transplantation. 2006:82:663-668. 3. De Paolis P, Favaro A, Piola A, et al. "ImmuKnow" to measurement of cell-mediated immunity in renal transplant recipients undergoing short-term evaluation. Transplant Proceedings. 2011;43:1013-1016.



www.LabCorp.com